ArticleThe American journal of case reports2025
Novel Sequential Therapy with Obinutuzumab and Telitacicept in Severe Lupus Nephritis with Glucocorticoid-Induced Avascular Necrosis (AVN) of the Femoral Head: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Systemic lupus erythematosus (SLE) is a common systemic autoimmune disease characterized by immune-mediated inflammation. Nearly half of SLE patients develop lupus nephritis (LN). Glucocorticoids are the most widely used foundational medication for SLE, yet their long-term use leads to a series of complications, such as opportunistic infections, diabetes, and femoral head osteonecrosis. Obinutuzumab is a humanized anti-CD20 monoclonal antibody, whereas telitacicept is a fusion protein that blocks B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL). Since monotherapy with B-cell depletion agents may lead to disease flare due to B-cell reconstitution and elevated levels of B-cell-stimulating factors (eg, BAFF), a new combination therapy involving B-cell depletion and BAFF/APRIL inhibitors could be an alternative to conventional therapies for patients, especially those with severe SLE. This combination has not yet been clinically applied. CASE REPORT We report the case of a 22-year-old woman with biopsy-proven class V LN 6 years ago, initially managed with prednisone, tacrolimus, and hydroxychloroquine. She developed glucocorticoid-induced femoral head necrosis 2 years after diagnosis and experienced recurrent lupus flares requiring multiple hospitalizations. At this admission for a critically severe lupus flare (SLEDAI score: 27), sequential treatment with Obinutuzumab followed by telitacicept resulted in effective remission of lupus activity. CONCLUSIONS This is the first reported case of severe SLE treated with sequential therapy involving Obinutuzumab followed by telitacicept. The combination therapy of B-cell depletion plus BAFF/APRIL inhibition could be a promising and rational treatment approach for SLE patients, especially those with severe SLE, which warrants further clinical trials to validate the efficacy and safety of the therapeutic regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.